The ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) study

Current Medical Research and Opinion

Volumn 20, Issue 9, 2004, Pages 1393-1401

  Didangelos, Triandafillos P ^a,d   Thanopoulou, A K ^b   Bousboulas, S H ^c   Sambanis, C L ^a   Athyros, V G ^a   Spanou, E A ^b   Dimitriou, K C ^c   Pappas, S I ^c   Karamanos, B G ^b   Karamitsos, D T ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c GENERAL HOSPITAL OF NIKEA   (Greece)

^d NONE   (Greece)

Author keywords

Cardiovascular risk; Diabetes; Diet; Metabolic syndrome; Orlistat

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIARRHEA; DISEASE DURATION; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LOW CALORY DIET; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OUTCOMES RESEARCH; RANDOMIZED CONTROLLED TRIAL; SMOKING; STATISTICAL ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ANTI-OBESITY AGENTS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIET, REDUCING; FEMALE; HUMANS; LACTONES; LIPASE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; RISK FACTORS;

EID: 5444251860     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904125004466     Document Type: Article

References (53)

1. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-9
2. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. J Am Med Assoc 2002;288:2709-16
3. Trevisan M, Liu J, Bahsas FB, Menotti A. Syndrome X and mortality: a population-based study. Am J Epidemiol 1998;148:958-66
4. Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 2004;173:307-12
5. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. [Third national health and nutrition examination survey (NHANES III). National Cholesterol Education Program (NCEP)]. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52:1210-4
6. Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the third national health and nutrition examination survey. Circulation 2004;109:42-6
7. Klein BE, Klein R, Lee KE. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care 2002;25:1790-4
8. Eriksson KF, Lindgärde F. Prevention of type 2 (non-insulin- dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmö feasibility study. Diabetologia 1991;34:891-8
9. Hellenius ML, de Faire U, Berglund B, Hamsten A, Krakau I. Diet and exercise are equally effective in reducing risk for cardiovascular disease. Results of a randomized controlled study in men with slightly to moderately raised cardiovascular risk factors. Atherosclerosis 1993;103:81-91
10. Haskell WL, Alderman EL, Fair JM, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation 1994;89:975-90
11. Rutledge JC, Hyson DA, Garduno D, Cort DA, Paumer L, Kappagoda CT. Lifestyle modification program in management of patients with coronary artery disease: the clinical experience in a tertiary care hospital. J Cardiopulm Rehabil 1999;19:226-34
12. Eriksson KF, Lindgärde F. No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmo Preventive Trial with diet and exercise. Diabetologia 1998;41:1010-6
13. Kramer FM, Jeffery RW, Forster JL, Snell MK. Long-term follow-up of behavioral treatment for obesity: patterns of weight regain among men and women. Int J Obes 1989;13:123-36
14. Wadden TA. Treatment of obesity by moderate and severe calorie restriction: results of clinical research trials. Arch Intern Med 1993;119:688-93
15. Grodstein F, Levine R, Troy L, Spencer T, Colditz GA, Stampfer MJ. Three-year follow-up of participants in a commercial weight loss program. Can you keep it off? Arch Intern Med 1996;156:1302-6
16. Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes, Obesity and Metabolism 2002;4:415-23
17. Lindgärde F, On Behalf Of The Orlistat Swedish Multimorbidity Study Group. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med 2000;248:245-54
18. Adult Treatment Panel III. The third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. J Am Med Assoc 2001;285:2486-97
19. Hermans MP, Levy J, Coppack S, Turner RC. Comparison of the efficiency of 4 in vivo insulin sensitivity tests to discriminate between individuals over the range of glucose tolerance by assessment of their Discriminant Ratio. Diabetes 1995;44 (Suppl. 1):201A
20. Mathiesen UL, Franzen LE, Aselius H, et al. Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases. Dig Liver Dis 2002;34:516-22
21. Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J 1986;292:13-5
22. Athyros VG, Bouloukos VI, Pehlivanidis AN, et al. The prevalence of the METabolic Syndrome in GREECE. The MetS-GREECE Multicenter Study. Diabetes Obes Metab [in press]
23. Athyros VG, Papageorgiou AA, Symeonidis AN, et al. Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Angiology 2003;54:679-90
24. Athyros VG, Papageorgiou AA, Mercouris BR, et al: Treatment with atorvastatin to the National Cholesterol Educational Program goals versus usual care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002;18:220-8
25. Zimmet P, Shaw J, Alberti KGMM. Preventing type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view. Diabetic Med 2003;20:693-702
26. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-61
27. Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab 2002;4:415-22
28. Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes. A 1-year randomized controlled trial. Diabetes Care 2002;25:1033-41
29. Montague CT, O'Rahilly S. The perils of portliness. Diabetes 2000;49:883-8
30. Bonora E, Targher G, Alberiche G, et al. Predictors of insulin sensitivity in type 2 diabetes. Diabetic Med 2002;19:535-42
31. Pi-Sunyer FX. Medical hazards of obesity. Ann Intern Med 1993;119:655-60
32. Brazilay JL, Abraham L, Heckbert SR. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 2001;50:384-9
33. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes 1992;16:397-415
34. Kanders BS, Peterson FJ, Lavin P, et al. Long term health effects associated with significant weight loss: a study of the dose response effect. In: Blackburn GL, Kanders BS, editors. Obesity pathophysiology, psychology and treatment. New York (NY): Chapman & Hall; 1994. p. 167-81
35. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk reduction in obese subjects treated for 2 years with orlistat. J Am Med Assoc 1999;281:235-42
36. Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998;352:167-72
37. Funahashi T, Nakamura T, Shimomura I, et al. Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. Int Med 1999;38:202-6
38. Valsamakis G, McTernan PG, Chetty R, et al. Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism 2004;53:430-4
39. Hotamisligil GS, Shargill NS, Spiegelmann BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity linked insulin resistance. Science 1993;259:87-91
40. Shimomura I, Hammer RE, Ikemoto S, et al. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999;401:73-6
41. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, glibenclamide or placebo in NIDDM patients. The Essen Study. Diabetes Care 1994;17:561-6
42. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin or placebo in dietary-treated NIDDM patients. The Essen-II Study. Am J Med 1997;103:483-90
43. Johansen K. Efficacy of metformin in the treatment of NIDDM: meta-analysis. Diabetes Care 1999;22:33-7
44. Kwiterovich Jr PO. Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity. Am J Cardiol 2002;90:30i-47i
45. Girman CJ, Rhodes T, Mercuri M, et al, for the 4S Group and the AFCAPS/TexCAPS Research Group. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004;93:136-41
46. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414-9
47. Wong ND, Pio JR, Franklin SS, L'Italien GJ, Kamath TV, Williams GR. Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. Am J Cardiol 2003;91:1421-6
48. Papadakis JA, Milionis HJ, Press M, Mikhailidis DP. Treating dyslipidaemia in non-insulin-dependent diabetes mellitus - a special reference to statins. J Diabetes Complications 2001;15:211-26
49. Davidson M, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. J Am Med Assoc 1999;281:235-42
50. Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998;352:167-72
51. Gokcel A, Gumurdulu Y, Karakose H, et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab 2002;4:49-55
52. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. J Am Med Assoc 2000;283:2404-10
53. Athyros VG, Elisaf M, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 2004;43:589-99